var data={"title":"Glucagon: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Glucagon: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6268?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=glucagon-patient-drug-information\" class=\"drug drug_patient\">see &quot;Glucagon: Patient drug information&quot;</a> and <a href=\"topic.htm?path=glucagon-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Glucagon: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F176479\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>GlucaGen Diagnostic;</li>\n      <li>GlucaGen HypoKit;</li>\n      <li>Glucagon Emergency</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14733086\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>GlucaGen;</li>\n      <li>GlucaGen HypoKit</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F176511\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antidote;</li>\n      <li>\n        Antidote, Hypoglycemia;</li>\n      <li>\n        Diagnostic Agent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F176481\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Diagnostic aid:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Relaxation of stomach, duodenal bulb, duodenum, and small bowel:</i></p>\n    <p style=\"text-indent:0em;margin-left:4em;\">IM: 1 mg</p>\n    <p style=\"text-indent:0em;margin-left:4em;\">IV: 0.2 to 0.5 mg</p>\n    <p style=\"text-indent:0em;margin-left:2em;\">\n      <i>Relaxation of colon:</i></p>\n    <p style=\"text-indent:0em;margin-left:4em;\">IM: 1 to 2 mg</p>\n    <p style=\"text-indent:0em;margin-left:4em;\">IV: 0.5 to 0.75 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Hypoglycemia:</b> IM, IV, SubQ: 1 mg; may repeat in 15 minutes as needed. <b>Note:</b>  IV dextrose should be administered as soon as it is available; if patient fails to respond to glucagon, IV dextrose must be given. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Anaphylactic reaction (refractory) in patients on beta-blocker therapy (off-label use):</b>  IV: Initial:  1 to 5 mg; followed by an infusion of 5 to 15 mcg/minute; titrate the infusion rate to achieve an adequate clinical response (Lieberman 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Beta-blocker- or calcium channel blocker-induced myocardial depression (with or without hypotension) unresponsive to standard measures (off-label use; AHA [Vanden Hoek 2010]; Bailey 2003): </b>IV: 3 to 10 mg (or 0.05 to 0.15 mg/kg) bolus followed by an infusion of 3 to 5 mg/hour (or 0.05 to 0.1 mg/kg/hour); titrate infusion rate to achieve adequate clinical response (AHA [Vanden Hoek 2010])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50991850\" class=\"block dora drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment (Adult)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50989145\" class=\"block doha drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment (Adult)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F176497\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=glucagon-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Glucagon: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Hypoglycemia: Note:</b> IV dextrose should be administered as soon as it is available; if patient fails to respond to glucagon, IV dextrose must be given.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants, Children, and Adolescents: IM, IV, SubQ:</p>\n    <p style=\"text-indent:0em;margin-left:4em;\">\n      <i>Glucagon Emergency Kit:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">&lt;20 kg: 0.5 mg or 0.02 to 0.03 mg/kg/dose; may repeat in 15 minutes as needed </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">&ge;20 kg: 1 mg; may repeat in 15 minutes as needed </p>\n    <p style=\"text-indent:0em;margin-left:4em;\">\n      <i>GlucaGen:</i></p>\n    <p style=\"text-indent:0em;margin-left:6em;\">\n      <i>Age-based dosing (if weight is unknown): </i></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Infants and Children &lt;6 years: 0.5 mg; may repeat in 15 minutes if needed</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Children &ge;6 years and Adolescents: 1 mg; may repeat in 15 minutes if needed</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Weight-based dosing:</i></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&lt;25 kg: 0.5 mg; may repeat in 15 minutes if needed</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&ge;25 kg: 1 mg; may repeat in 15 minutes if needed</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Anaphylactic reaction (refractory) in patients on beta-blocker therapy (off-label use):</b> Children: IV: Initial: 20 to 30 <b>mcg/kg</b> (maximum: 1 mg); followed by an infusion of 5 to 15 <b>mcg/minute</b>; titrate the infusion rate to achieve an adequate clinical response (Lieberman 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Beta-blocker- or calcium channel blocker-induced myocardial depression (with or without hypotension) unresponsive to standard measures (off-label use):</b> IV: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children: Initial bolus of 30 to 150 <b>mcg</b>/kg followed by an infusion of 70 <b>mcg</b>/kg/hour (maximum: 5 mg/hour) (Hegenbarth 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adolescents: Initial: 5 to 10 mg over several minutes followed by infusion of 1 to 5 mg/hour (Hegenbarth 2008; PALS [Kleinman 2010])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51112191\" class=\"block dorp drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment (Pediatric)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51112192\" class=\"block dohp drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment (Pediatric)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F176482\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F176459\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Kit, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Glucagon Emergency: 1 mg [contains lactose]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">GlucaGen Diagnostic: 1 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">GlucaGen HypoKit: 1 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 mg (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F176444\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F176462\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diagnostic aid: For IM or IV administration. If given IV, administer over 1 minute. After the diagnostic procedure, administer oral carbohydrates to patients who have been fasting, if this is compatible with the diagnostic procedure applied. Bolus IV doses &gt;1 mg are not recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypoglycemia: For SubQ, IM, or IV administration in the upper arms, thighs, or buttocks. Administer fast-acting and long-acting oral carbohydrates to patient as soon as possible after response to treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Rapid injection may be associated with increased nausea and vomiting; place patient in lateral recumbent position to protect airway (Liberman 2010) and to prevent choking when consciousness returns. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anaphylactic reaction (refractory) in patients on beta-blocker therapy: Administer bolus over 5 minutes (Lieberman 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta-blocker/calcium channel blocker toxicity: Administer bolus over 3 to 5 minutes; continuous infusions may be used. Ensure adequate supply available to continue therapy (AHA [Vanden Hoek 2010]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14472642\" class=\"block uica drugH1Div\"><span class=\"drugH1\">Usual Infusion Concentrations: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>IV infusion:</b> 4 mg in 50 mL (concentration: 0.08 mg/mL) of D<sub>5</sub>W </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F176460\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Diagnostic aid</b>: As a diagnostic aid during radiologic examinations to temporarily inhibit movement of the GI tract in adults.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypoglycemia:</b> Treatment of severe hypoglycemia in pediatric and adult patients.<b> Note:</b> The American Diabetes Association (ADA) recommends that glucagon be prescribed for all diabetic patients at increased risk of clinically significant hypoglycemia (&lt;54 mg/dL); caregivers, school personnel, or family members of these patients should be trained on when and how to administer glucagon (ADA 2018).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Limitations of use: Products not packaged with a syringe and diluent necessary for rapid preparation and administration during an emergency outside of a health care facility are not indicated for the emergency treatment of hypoglycemia.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25474760\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Anaphylactic reactions; Beta-blocker-induced myocardial depression; Calcium channel blocker-induced myocardial depression</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F176451\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Hypertension, hypotension (up to 2 hours after GI procedures), increased blood pressure, increased pulse, tachycardia </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Nausea, vomiting (high incidence with rapid administration of high doses) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Miscellaneous: Anaphylaxis, hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&lt;1%, postmarketing, and/or case reports: Abdominal pain, hypoglycemia, hypoglycemic coma, respiratory distress, urticaria</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F176465\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Known hypersensitivity to glucagon, lactose, or any component of the formulation; pheochromocytoma; insulinoma; glucagonoma (excluding GlucaGen)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F176448\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypersensitivity reactions: Allergic reactions including skin rash and anaphylactic shock (with hypotension and respiratory difficulties) have been reported; reactions have generally been associated with endoscopic patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Adrenal insufficiency: Use with caution in patients with adrenal insufficiency; levels of glucose stores in liver may be decreased. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Cardiac disease: Use with caution in patients with cardiac disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Chronic hypoglycemia: Use with caution in patients with chronic hypoglycemia; levels of glucose stores in liver may be decreased.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Diabetes: Use caution if using as diagnostic aid in patients with diabetes on insulin; may cause hyperglycemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Glucagonoma: Use with caution in patients with glucagonoma. The use of glucagon is contraindicated in patients with this condition (excluding GlucaGen).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Insulinoma: Exogenous glucagon may cause an initial rise in blood glucose followed by rebound hypoglycemia. The use of glucagon is contraindicated in patients with this condition.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pheochromocytoma: Exogenous glucagon may cause the release of catecholamines, resulting in an increase in blood pressure. The use of glucagon is contraindicated in patients with this condition.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Starvation/fasting: Use caution with prolonged fasting and/or starvation; levels of glucose stores in liver may be decreased.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Lactose: May contain lactose; avoid administration in hereditary galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: Insulin or sulfonylurea overdose: Patients with hypoglycemia should immediately be treated with dextrose. If IV access cannot be established or if dextrose is not available, glucagon may be considered as alternative acute treatment until dextrose can be administered.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Secondary hypoglycemia: Supplemental carbohydrates should be given to patients who respond to glucagon for severe hypoglycemia to prevent secondary hypoglycemia.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299406\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F176453\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8493&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Anticholinergic Agents: May enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Indomethacin: May diminish the therapeutic effect of Glucagon.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Glucagon may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F176477\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Glucagon depletes glycogen stores.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F176455\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13882222\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13882223\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Glucagon is not absorbed from the GI tract and therefore, it is unlikely adverse effects would occur in a breast-feeding infant.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F176468\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Administer oral carbohydrates to patient as soon as possible after response to treatment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F176457\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Blood pressure, blood glucose, ECG, heart rate, mentation; signs or symptoms of a hypersensitivity reaction.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50511144\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Classification of hypoglycemia (ADA 2018):</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypoglycemia alert value (level 1): &le;70 mg/dL (sufficiently low for treatment with fast-acting carbohydrate and dose adjustment of glucose-lowering therapy)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clinically significant hypoglycemia (level 2): &lt;54 mg/dL (sufficiently low to indicate serious, clinically important hypoglycemia)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Severe hypoglycemia (level 3): No specific glucose threshold (hypoglycemia associated with severe cognitive impairment requiring external assistance for recovery)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F176447\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">Stimulates adenylate cyclase to produce increased cyclic AMP, which promotes hepatic glycogenolysis and gluconeogenesis, causing a raise in blood glucose levels; antihypoglycemic effect requires preexisting hepatic glycogen stores. Extra hepatic effects of glucagon include relaxation of the smooth muscle of the stomach, duodenum, small bowel, and colon.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F176464\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Blood glucose levels: Peak effect: IV: 5 to 20 minutes; IM: 30 minutes; SubQ: 30 to 45 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">GI relaxation: IV: 45 seconds; IM: 4 to 10 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration:</p>\n    <p style=\"text-indent:0em;margin-left:2em;\">Glucose elevation: IV, IM, SubQ: 60 to 90 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">GI relaxation: IV: 9 to 25 minutes; IM: 12 to 32 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: ~0.25 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Primarily hepatic; some inactivation occurring renally and in plasma </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination, plasma: IV: 8 to 18 minutes; IM (apparent): 26 to 45 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: IM: ~10 to 12.5 minutes; SubQ: 20 minutes </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2524623\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Glucagon Emergency Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg (1): $336.96</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (GlucaGen Diagnostic Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg (1): $205.92</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (GlucaGen HypoKit Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg (1): $325.75</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Glucagon HCl (Diagnostic) Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg (1): $204.60</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F176469\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Garcon (KR);</li>\n      <li>Glucagen (AE, AR, AU, BB, BE, BH, BR, CH, CL, CO, CU, CY, DE, DK, EC, ES, FR, GR, HK, IE, IN, IT, JO, KW, LB, LK, MY, NZ, PL, PY, SA, TH, UY, ZA);</li>\n      <li>GlucaGen (AT, FI, GB, HR, HU, IE, IL, IS, LT, LU, LV, MT, NL, PT, QA, SG, SI, SK, TR, VN);</li>\n      <li>Glucagen G (JP);</li>\n      <li>Glucagen Novo (HK);</li>\n      <li>Glucagon Novo Nordisk (SE);</li>\n      <li>R-Glucagon Lilly (MX)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"29222377\"></a>American Diabetes Association (ADA). 6. Glycemic targets: standards of medical care in diabetes-2018. <i>Diabetes Care</i>. 2018;41(suppl 1):S55-S64. doi: 10.2337/dc18-S006.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/glucagon-drug-information/abstract-text/29222377/pubmed\" target=\"_blank\" id=\"29222377\">29222377</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"14514004\"></a>Bailey B, &ldquo;Glucagon in Beta-Blocker and Calcium Channel Blocker Overdoses: A Systematic Review,&rdquo; <i>J Toxicol Clin Toxicol</i>, 2003, 41(5):595-602.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/glucagon-drug-information/abstract-text/14514004/pubmed\" target=\"_blank\" id=\"14514004\">14514004</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Glucagon injection [prescribing information]. Lake Zurich, IL: Fresenius Kabi; January 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    GlucaGen HypoKit and Diagnostic Kit (glucagon) [prescribing information]. Plainsboror, NJ: Novo Nordisk; December 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Glucagon Emergency Kit [prescribing information]. Indianapolis, IN: Eli Lilly and Company; September, 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hegenbarth MA and American Academy of Pediatrics Committee on Drugs, &quot;Preparing for Pediatric Emergencies: Drugs to Consider,&quot; <i>Pediatrics</i>, 2008, 121(2):433-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/glucagon-drug-information/abstract-text/18245435/pubmed\" target=\"_blank\" id=\"18245435\">18245435</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Holger JS, Engebretsen KM, Obetz CL, et al, &quot;A Comparison of Vasopressin and Glucagon in Beta-Blocker Induced Toxicity,&quot; <i>Clin Toxicol (Phila)</i>, 2006, 44(1):45-51.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kleinman ME, Chameides L, Schexnayder SM, et al. Part 14: pediatric advanced life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Circulation</i>. 2010;122(18 suppl 3):S876-S908.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/glucagon-drug-information/abstract-text/20956230/pubmed\" target=\"_blank\" id=\"20956230\">20956230</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20692689\"></a>Lieberman P, Nicklas RA, Oppenheimer J, et al. The diagnosis and management of anaphylaxis practice parameter: 2010 update [published correction appears in [<i>J Allergy Clin Immunol</i>. 2010;126(6):1104]. <i>J Allergy Clin Immunol</i>. 2010;126(3):477-480.e1-e42.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/glucagon-drug-information/abstract-text/20692689/pubmed\" target=\"_blank\" id=\"20692689\">20692689</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Love JN, Sachdeva DK, Bessman ES, et al, &quot;A Potential Role for Glucagon in the Treatment of Drug-Induced Symptomatic Bradycardia,&quot; <i>Chest</i>, 1998, 114(1):323-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/glucagon-drug-information/abstract-text/9674488/pubmed\" target=\"_blank\" id=\"9674488\">9674488</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mokhlesi B, Leikin JB, Murray P, et al, &ldquo;Adult Toxicology in Critical Care: Part II: Specific Poisonings,&rdquo; <i>Chest</i>, 2003, 123(3):897-922.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/glucagon-drug-information/abstract-text/12628894/pubmed\" target=\"_blank\" id=\"12628894\">12628894</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trujillo MH, Guerrero J, Fragachan C, et al, &quot;Pharmacologic Antidotes in Critical Care Medicine: A Practical Guide for Drug Administration,&quot; <i>Crit Care Med</i>, 1998, 26 (2): 377-391.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vanden Hoek TL, Morrison LJ, Shuster M, et al, &quot;Part 12: Cardiac Arrest in Special Situations: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&quot; <i>Circulation</i>, 2010, 122(18 Suppl 3):829-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/glucagon-drug-information/abstract-text/20956228/pubmed\" target=\"_blank\" id=\"20956228\">20956228</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wax PM, Erdman AR, Chyka PA, et al, &ldquo;Beta-Blocker Ingestion: An Evidence-Based Consensus Guideline for Out-of-Hospital Management,&rdquo; <i>Clin Toxicol (Phila)</i>, 2005, 43(3):131-146.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8493 Version 141.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F176479\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F14733086\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F176511\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F176481\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment (Adult)\" href=\"#F50991850\" class=\"outlineLink\">Dosing: Renal Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment (Adult)\" href=\"#F50989145\" class=\"outlineLink\">Dosing: Hepatic Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F176497\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment (Pediatric)\" href=\"#F51112191\" class=\"outlineLink\">Dosing: Renal Impairment (Pediatric)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment (Pediatric)\" href=\"#F51112192\" class=\"outlineLink\">Dosing: Hepatic Impairment (Pediatric)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F176482\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F176459\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F176444\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F176462\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Usual Infusion Concentrations: Adult\" href=\"#F14472642\" class=\"outlineLink\">Usual Infusion Concentrations: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F176460\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25474760\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F176451\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F176465\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F176448\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299406\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F176453\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F176477\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F176455\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F13882222\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F13882223\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F176468\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F176457\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F50511144\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F176447\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F176464\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F2524623\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F176469\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8493|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=glucagon-patient-drug-information\" class=\"drug drug_patient\">Glucagon: Patient drug information</a></li><li><a href=\"topic.htm?path=glucagon-pediatric-drug-information\" class=\"drug drug_pediatric\">Glucagon: Pediatric drug information</a></li></ul></div></div>","javascript":null}